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ABSTRACT
Introduction Myeloperoxidase (MPO), an enzyme linking obesity and cardiovascular (CV) risk in adults, has
rarely been studied in young children and no studies assessed its association with renal function. We sought to
explore a possible association between serum MPO levels, obesity, CV risk factors and renal function in
prepubertal children.
Materials/Methods Cross-sectional evaluation of 309 children aged 8–9 years (161 normal weight, 148 over-
weight/obese), members of the birth cohort Generation XXI (Portugal). Anthropometrics (body mass index
(BMI), waist-to-height ratio (WHtR) and % body fat mass (%BFM) by bioelectrical impedance analysis), 24-h
ambulatory blood pressure monitoring and pulse wave velocity (PWV) were measured. Insulin resistance was
estimated by the HOMA index (considering serum fasting glucose and insulin determinations). Serum MPO
levels were assessed by immunoenzymatic assay.
Results MPO levels were positively associated with obesity indices (BMI z-score, WHtR and %BFM). Higher
MPO levels were associated with higher 24-h and night-time mean arterial pressure, with nondipping and with
higher values of insulin resistance. In normal weight children, the endothelial function, as evaluated indirectly by
PWV, was an independent predictor of MPO levels. In overweight/obese children, estimated glomerular filtra-
tion rate increased significantly across tertiles of MPO (Ptrend = 0031) and this association held after adjustment
for age, sex, neutrophil and monocyte counts and CV risk factors.
Conclusions Our results reinforce the role of MPO as a risk marker in obesity and related CV morbidities in
young children. MPO levels associate with the dipping pattern and PWV and, among overweight/obese children,
an association exists between MPO and renal function.
Keywords Blood pressure, childhood obesity, glomerular filtration rate, myeloperoxidase, pulse wave velocity.
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Introduction
Obesity is a state of low-grade inflammation and associated
oxidative stress, which are thought to be key factors in the
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pathogenesis of cardiovascular (CV) diseases and early phases
of endothelial dysfunction [1]. Obese children already present a
proinflammatory state [2] and increased levels of oxidative
stress [3].
Myeloperoxidase (MPO) is an enzyme most abundantly
expressed in neutrophils and monocytes that is associated to
both inflammation and oxidative stress, as well as linked to the
initiation and progression of acute and chronic inflammatory
diseases [4]. MPO-derived substances are thought to cause
important damage to endogenous cells, especially in the arterial
wall, where MPO-catalysed reactions promote the oxidation of
low-density lipoprotein (LD) potentially contributing to
atherogenesis [5].
In adults, circulating MPO concentrations are higher in obese
subjects [6,7], associated with blood pressure (BP) indepen-
dently of other traditional CV risk factors [8], and predict CV
risk [9–11]. Besides, MPO plays a major role in chlorination and
nitration of high-density lipoprotein (HDL) in atherosclerotic
tissue, depriving HDL of its cardioprotective effects [12].
Elevated MPO levels are also observed in adults with
chronic kidney disease (CKD) before and after dialysis initia-
tion [13–15], but the evolution of MPO levels with loss of
residual renal function is controversial.
In children, there is little evidence of MPO being associated
with CV risk and no study explored its relationship with renal
function. Recently, elevated MPO levels were reported in a
sample of healthy prepubertal children, in association with
obesity and other CV risk factors [16]. Another study found
higher MPO concentrations in severely obese as compared to
normal weight children, but observed no differences in several
macro- and microcirculation parameters at baseline or after a 4-
month weight loss programme, although MPO levels decreased
[17].
We set out to explore the role of MPO in the context of CV
comorbidities in young children. In this study, we aimed to
determine whether, in prepubertal children, serum MPO levels
are associated with measures of obesity and other CV risk
factors. As it is established that obesity generates a milieu
favourable to some degree of renal impairment [18], we also
aimed to assess the link between MPO and renal function and
to determine putative interactions with obesity.
Methods
Study design and sample
We studied children aged 8–9 years that have been followed
since birth in a previously established cohort study (Generation
21, Porto, Portugal) [19]. Subjects from the original cohort were
eligible for this study protocol (ObiKid project) if they had
anthropometric data and a blood sample withdrawn at the 7-
year-old evaluation (n = 4590). We aimed to include a mini-
mum sample of 300 children for the Obikid project’s main
objective, assuming that about 35% would be excluded due to
refusal to participate, exclusion criteria or incomplete infor-
mation, 463 children were preselected to be consecutively
screened according to the date of their 7-year-old evaluation: 16
could not be contacted, 32 refused to participate, 23 were
unable to schedule the study visits during the recruitment
period and 68 met exclusion criteria (four chronic diseases, one
chronic usage of medication, 51 living far from the study site
and 12 twins). We finally enrolled 324 participants, between
August 2013 and August 2014. For the present analysis, 15
children were additionally excluded due to incomplete evalu-
ation, such as absence of blood sample or MPO determination
(14), or due to BMI classification as underweight (1). This final
sample size (n = 309) provides a statistical power of 86% to
detect a difference in MPO levels between normal weight and
overweight/obese children of at least 8 ng/mL (assuming SD
of 19 and 27 ng/mL in each group, respectively) [20].
Data collection and variable definition
The study visits took place at the Department of Clinical Epi-
demiology, Predictive Medicine and Public Health, Faculty of
Medicine of University of Porto. Anthropometric and general
physical examination were performed, according to standard
procedures and as previously reported [21]. Waist circumfer-
ence was indexed to height (waist-to-height ratio, WHtR in cm/
m) for statistical analysis. Body mass index (BMI) values were
classified according to the World Health Organization reference
data for BMI z-score into the following categories: normal
weight [> 2 and ≤ +1 standard deviation (SD)] and over-
weight/obesity (> 1SD) [22]. In our sample, 88 (285%) of 89
(288%) children are overweight and 60 (194%) of 36 (117%)
are obese, according to the WHO reference [22] and the IOTF
reference [23], respectively. Body fat percentage was assessed
by foot-to-foot bioelectrical impedance analysis (Tanita, model
TBF-300, Arlington Heights, IL, USA).
Ambulatory blood pressure monitoring (ABPM) for 24 h was
performed in all children with a portable noninvasive oscillo-
metric blood pressure recorder (Spacelabs Healthcare, model
90207, Snoqualmie, WA, USA). The nondominant arm was
used in all children with an appropriate cuff size. BP mea-
surements were taken automatically at 20-min intervals during
the daytime and at 30-min intervals during the night-time. A
minimum monitoring duration of 24 h with gaps of less than
2 h was required for acceptance; five exams were excluded due
to insufficient readings. Hypertension was defined as an aver-
age systolic (SBP) and/or diastolic blood pressure (DBP) mea-
surements ≥ 95th percentile, during the day or the night,
according to the reference values [24]. The absence of dipping
pattern was considered as a fall in the MAP during night-time
of less than 10% of the corresponding daytime BP.
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Carotid-femoral pulse wave velocity (PWV) analysis was
performed by a single trained cardiopneumology technician
with a portable device (Micro Medical, model PulseTrace
PWV PT4000, Kent, UK); digital volume pulse waveform had
to fill 2/3 of the display with little or no noise and artefact to
be considered and three measurements of PWV were per-
formed and averaged for analysis. Adequate PWV measure-
ments were available for 308 of the 309 children included in
the analysis.
A venous blood sample was collected from all the partici-
pants, in the morning period, after an overnight fast of at least
8 h. All the standard laboratory analyses were performed in the
Clinical Pathology Department of Centro Hospitalar São João,
Porto – Portugal. Insulin resistance was determined using the
homoeostasis model assessment index (HOMA-IR) (3 children
with missing data). The Zappitelli combined formula was used
to estimate GFR (eGFR) [25]. The serum concentration of MPO
was assessed in the Department of Pharmacology and Thera-
peutics of the Faculty of Medicine of the University of Porto by
an immunoenzymatic method, using a commercial ELISA kit
(BioCheck MPO Enzyme Immunoassay, Oxis International
Inc., Tampa, FL, USA).
Ethics
The ObiKid study was approved by the Ethics Committee of
Centro Hospitalar São João, Porto – Portugal and Faculty of
Medicine of the University of Porto and it complies with the
Helsinki Declaration and the current national legislation.
Written informed consent from parents (or their legal substi-
tute) and verbal assent from children were obtained.
Table 1 General characteristics and biochemical parameters by classes of body mass index
WHO BMI z-score classification
P
Normal weight Overweight Obese
n = 161 n = 88 n = 60
Age (months) 105  3 105  3 106  3 0458
Male sex 82 (51%) 43 (49%) 39 (65%) 0114
BMI z-score 001  070 156  030 266  048 < 0001
WHtR (cm/m) 45  3 50  3 57  5 < 0001
% body fat mass 108  72 201  79 281  94 < 0001
24-h mean arterial pressure (mmHg) 811  44 824  52 826  63 0054
Daytime mean arterial pressure (mmHg) 848  46 857  57 860  65 0229
Night-time mean arterial pressure (mmHg) 733  48 747  52 752  62 0026
Absence of dipping pattern 34 (22%) 30 (34%) 16 (27%) 0104
Pulse wave velocity (m/sec) 498  049 503  052 520  050 0013
Leucocyte count (9 109/L) 611  175 630  180 655  162 0250
Neutrophil count (9 109/L) 278  135 296  134 312  119 0197
Monocyte count (9 109/L) 052  019 054  020 059  018 0038
Total cholesterol (mg/dL) 157  25 163  28 162  25 0142
HDL cholesterol (mg/dL) 55  11 54  10 52  9 0182
Triglycerides (mg/dL) 53  20 62  30 69  33 < 0001
Fasting glucose (mg/dL) 858  54 854  53 872  49 0105
Fasting insulin (lIU/mL) 57  24 71  29 94  51 < 0001
HOMA-IR 113 (084–139) 146 (107–184) 168 (128–264) < 0001
High-sensitivity C-reactive protein (mg/L) 00 (00–04) 05 (02–12) 08 (03–19) < 0001
Interleukin-6 (pg/mL) 075 (075–243) 159 (075–332) 198 (075–302) 0069
The values presented are mean  standard deviation or median (interquartile range), except for sex and the absence of dipping pattern (n (%)). The groups of
BMI (normal weight, overweight and obesity) were defined according to the WHO classification for BMI z-score (19).
BMI, body mass index; WHtR, waist-to-height ratio; HOMA-IR – homoeostasis model assessment of insulin resistance.
52 ª 2015 Stichting European Society for Clinical Investigation Journal Foundation
L. CORREIA-COSTA ET AL. www.ejci-online.com
Statistical analysis
Data are presented as mean and SD or, if skewed, as median
and interquartile range (IQR). MPO had an asymmetric dis-
tribution and was logarithmized (base 10) before linear
regression analyses, allowing to obtain a normal distribution.
Bivariate associations were assessed by Spearman correlation
tests. Linear trend was tested using linear regression models
with tertiles of MPO and classes of adiposity measures
included as independent continuous variables. Linear
regression analysis was used to identify independent deter-
minants of MPO and to assess the relationship between MPO
and GFR, stratifying by BMI. Reporting of the study con-
forms to STROBE statement [26,27].
Results
A total of 309 children (53% male) with a mean (SD) age of 88
(02) years were included in the present analysis. Clinical
characteristics and levels of biochemical parameters of all study
subjects and separately for normal weight (n = 161) and over-
weight/obese children (n = 148, of whom 88 overweight and 60
obese) are shown in Table 1.
As shown in Table 2, all measures of obesity (BMI, BMI
z-score, WHtR and % body fat mass) significantly increased
across tertiles of MPO and older children presented signifi-
cantly higher levels of MPO. Regarding BP, 24-h and night-time
MAP increased across tertiles of MPO and the absence of a
dipping pattern was also more frequent among children in the
Table 2 General characteristics and biochemical parameters by tertiles of serum myeloperoxidase
Serum myeloperoxidase (MPO)
P
1st Tertile 2nd Tertile 3rd Tertile
[255–4074] ng/mL [4074–7297] ng/mL [7297–35915] ng/mL
Age (months) 105  3 105  3 106  3 0001
Male sex 58 (56%) 47 (46%) 59 (57%) 0190
BMI z-score 050  123 082  109 152  117 < 0001
WHtR (cm/m) 47  5 48  5 51  6 < 0001
% body fat mass 130  101 165  93 210  105 < 0001
24-h mean arterial pressure (mmHg) 804  48 827  53 822  49 0015
Daytime mean arterial pressure (mmHg) 844  51 860  55 854  54 0173
Night-time mean arterial pressure (mmHg) 723  48 751  57 748  48 0001
Absence of dipping pattern 16 (16%) 32 (31%) 32 (32%) 0012
Pulse wave velocity (m/sec) 501  051 503  047 506  054 0508
Leucocyte count (9 109/L) 582  152 615  146 680  205 < 0001
Neutrophil count (9 109/L) 249  096 275  100 346  167 < 0001
Monocyte count (9 109/L) 050  018 052  017 059  021 0002
Total cholesterol (mg/dL) 161  29 160  26 157  22 0362
HDL cholesterol (mg/dL) 54  11 55  10 52  9 0218
Triglycerides (mg/dL) 57  23 59  26 61  30 0232
Fasting glucose (mg/dL) 864  55 860  52 853  52 0139
Fasting insulin (lIU/mL) 62  30 69  35 74  40 0017
HOMA-IR 124 (097–157) 126 (093–185) 141 (105–195) 0035
High-sensitivity C-reactive protein (mg/L) 00 (00–05) 03 (00–08) 04 (00–11) 0015
Interleukin-6 (pg/mL) 075 (075–238) 173 (075–242) 195 (075–332) 0005
The values presented are mean  standard deviation or median (interquartile range), except for sex and the absence of dipping pattern (n (%)). The tertiles of
myeloperoxidase (≤ 407; 407–730; > 730) were defined based on all enrolled participants.
BMI, body mass index; WHtR, Waist-to-height ratio; HOMA-IR – homoeostasis model assessment of insulin resistance.
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higher MPO tertiles. Total white blood cell, neutrophil and
monocyte counts also significantly increased across tertiles of
MPO. Higher levels of hsCRP and IL-6 levels were found in
children with higher levels of MPO.
The medians and interquartile range (IQR) of serum MPO
levels by classes of BMI and tertiles of WHtR and percentage of
body fat mass are shown in Fig. 1. All linear trend analyses
across groups were adjusted for sex and age (in months). The
normal weight children presented significantly lower levels of
MPO than overweight or obese children (426 (IQR: 268 to
622), 722 (522 to 1065), 824 (489 to 1054) ng/mL, respec-
tively; Ptrend < 0001). Concordantly, a pattern of increasing
median MPO levels across tertiles of WHtR and % body fat
mass was found.
In the univariate linear regression analysis, age (in months)
and the neutrophil count were associated with serum MPO in
the normal weight group, and neutrophil and monocyte counts
in the overweight/obesity group (Table 3). After adjusting for
all the variables of interest, in the normal weight group MPO
increased significantly with age (by +75 ng/mL per month of
age), with neutrophil count (by +170 per 1 9 109/L of neu-
trophils) and with PWV (by 315 ng/mL per m/s of PWV) and
decreased significantly with monocytes count (by 725 per
1 9 109/L of monocytes). In the overweight/obesity group, the
only independent determinant of MPO was the neutrophil
count (increase of 107 ng/mL in MPO per 19 109/L of neu-
trophils) (Table 3). The effect of age and PWV on MPO levels
decreased across BMI classes, being significantly lower in obese
compared to normal weight children (P for interaction = 0036
and 0010, respectively).
In normal weight children, no significant association was
found between MPO levels and renal function, whereas in
overweight/obese children, levels of eGFR increased signifi-
cantly across tertiles of MPO (133 (125 to 146), 135 (122 to 142),
135 (126 to 145) mL/min/173 m2, Ptrend = 0031) (Fig. 2). This
association of MPO levels with eGFR levels proved to be strong
and to hold in a fully adjusted multivariate model, with eGFR
increasing by 99 (95% confidence interval: 05 to 194,
P = 0040) per logarithm of ng/mL of MPO (Table 4).
Discussion
In this study in more than 300 healthy prepubertal children,
MPO levels were higher in the presence of obesity, irrespec-
tively of the measure considered. MPO was also associated
with other important markers of CV risk, namely the loss of the
BP dipping pattern. While in overweight/obese subjects, only
the neutrophil count was an independent determinant of MPO
levels, in the normal weight endothelial function, as evaluated
indirectly by the PWV, was also an independent predictor of
the levels of MPO. In addition, we found a strong positive
association of MPO with eGFR levels in overweight/obese
Figure 1 Distribution of serum myeloperoxidase levels by classes of body mass index (BMI) and tertiles of waist-to-height ratio
and percentage of body fat mass. The normal weight, overweight and obese group classification is according to the WHO
classification for BMI z-score (ref. 24). The tertiles of waist-to-height ratio (≤ 4569; 4570–5000; >5000) and % of body fat mass
(≤ 1143; 1144–2070; >2070) were defined based on all enrolled participants. The myeloperoxidase data are expressed as medians
and percentiles 25 and 75. P values for linear trend across groups were calculated by linear regression, adjusting for age (in months)
and sex.
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children, which held after adjustment for several CV risk
factors.
The finding that MPO levels associate with obesity is well
established in adults [6,7]. Our findings that MPO levels are
higher in overweight and obese children and increase across
WHtR and % body fat mass tertiles are in accordance with the
few studies that exist in children. Two recent studies in pre-
pubertal children and another in adolescents reported that
MPO, considered as a biomarker of CVD, was significantly
higher in the obese children [17,20,28]. Another study found
increased levels of MPO and others markers of oxidative stress,
inflammation and endothelial activation in obese children with
vitamin D insufficiency [29]. hsCRP is a biomarker of CV risk in
adults and both hsCRP and IL-6 are known to interfere with
endothelial function, in part by stimulating inflammation-
oxidative stress pathways [1]. In our study, both hsCRP and
IL-6 levels increased across tertiles of MPO, which is concor-
dant with the positive significant correlations found by Olza
et al. [16].
MPO is regarded as a common link between inflammation
and oxidative stress systems and closely related to the vascular
wall. In our study, we observed that higher MPO levels are
associated with increasing levels of 24-h and night-time BP and
with the loss of the dipping pattern. To our knowledge, no
previous studies addressed the association of MPO levels and
ABPM as completely as we have done. Evidence supports that,
even in children, ABPM is more accurately related with target-
organ damage and is a better predictor of CV risk than office BP
measurements [30,31]. Also, in adults, the nondipping pattern
seems to increase the risk of BP-related complications and
overall mortality [32]. However, the prevalence of nondipping
in the general paediatric population before the onset of
Figure 2 Distribution of estimated glomerular filtration rate by tertiles of serum myeloperoxidase, in the normal weight and
overweight/obesity groups. The tertiles of myeloperoxidase (≤ 407; 407–730; > 730) were defined based on all enrolled
participants. The eGFR data are expressed as medians and percentiles 25 and 75. The value of P for linear trend was estimated by
linear regression analysis of eGFR levels on MPO levels, adjusting for age (in months) and sex. The normal weight group includes
only children with normal weight, and the overweight/obesity group includes children with overweight or obesity, according to the
WHO classification for BMI z-score [22]. eGFR, estimated glomerular filtration rate by Zappitelli combined formula.
Table 4 Mean changes in estimated glomerular filtration rate
per logarithm of serum myeloperoxidase in the overweight/
obesity group
eGFR (mL/min/173 m2)
b (95% CI) P
MPO (crude) 110 (22 to 199) 0015
MPO + age (months) + sex 108 (18 to 198) 0019
Fully adjusted model* 99 (05 to 194) 0040
The values presented are linear regression coefficients (b) and 95% confi-
dence intervals, estimated by multiple linear regression, with eGFR (esti-
mated glomerular filtration rate by Zappitelli combined formula) as
dependent variable and serum myeloperoxidase (transformed by logarithm
with base 10) as independent variable, adjusting for several variables as
stated.
*The fully adjusted model is adjusted for sex and age (in months), BMI
z-score, hypertension (defined as an average systolic and/or diastolic blood
pressure measurements ≥ 95th percentile, either during the day or the night,
according to Urbina et al. reference tables [24]), pulse wave velocity, neu-
trophil count, monocyte count, insulin resistance by homoeostasis model
assessment (transformed by logarithm with base 10) and HDL cholesterol.
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hypertension or in the setting of obesity is largely unknown. A
review from 2009, states that, in children, BMI correlates with
ABPM, especially with systolic and night-time BP, but that the
dipping is not consistently affected across studies [33]. The
physiological mechanisms behind loss of dipping are still
unclear, but it is hypothesized that it might be related to
changes in insulin–glucose metabolism. In fact, in adults, MPO
was positively and independently associated with office SBP
and DBP and the association was stronger in the presence of
hyperglycaemia or oxidative stress [8]. In another study in
adults, a specific antihypertensive treatment reduced both
ABPM and inflammatory and oxidative biomarkers, including
MPO [34]. However, previous studies in young children failed
to find an association between dipping and insulin resistance
[35,36]. Accordingly, in our study, we found no association
between glucose, insulin or HOMA-IR levels and the dipping
pattern (data not shown).
Childhood BP tracks into adult life and represents one of the
most important predictors of CV risk in later life [37]. Thus, the
fact that prepubertal overweight/obese children with higher
levels of MPO already had higher night-time BP raises the
possibility that, at this age, MPO-derived reactive substances
may already be associated with injury to the arterial wall. Our
novel finding that in normal weight children MPO levels were
independently associated with PWV reinforces this hypothesis,
suggesting that MPO might contribute to vascular stiffness and
atherogenesis, even at prepubertal age. The capacity of MPO to
reduce the availability of the endogenous vasodilator nitric
oxide and the possible interference with lipids in the vascular
wall have been proposed as possible mechanisms of injury
[12,38,39]. Although a recent study found no differences in
brachial artery or microvascular reactivity in severely obese
children with higher levels of MPO, PWV was not evaluated
[17]. In addition, we found that most of the independent
determinants of MPO in normal weight children were not sig-
nificant in the overweight/obesity subgroup of our cohort,
suggesting that obesity, per se, is an important and strong
determinant of MPO. Actually, there were significant interac-
tions between BMI z-score categories and both age and PWV,
with the effect of these variables decreasing across BMI classes.
While insulin and HOMA-IR did not independently predict
MPO, this might be explained by the fact that only few children
in our sample were insulin-resistant by the HOMA-IR criterion.
Our findings concerning the association of MPO with renal
function in overweight/obese children were somewhat unex-
pected. It is well established that obesity initially causes phys-
iological (mal)adaptation of the kidney with hyperfiltration and
hyperperfusion consequently leading to proteinuria and pro-
gressive renal damage [40]. We speculate that the overweight/
obese children with higher GFR in our cohort might be subject
to such glomerular hyperfiltration, and MPO might be directly
involved in this process. Ex vivo perfusion of glomeruli with
MPO and H2O2 has been demonstrated to induce proteinuria,
endothelial cell swelling, and epithelial cell foot process
effacement [41] and local MPO activity contributes to
glomerular damage in experimental glomerulonephritis [42].
Strengths and limitations
Our study covers a novel area of investigation and adds
important findings regarding MPO as a biomarker of long-term
CV risk in young children. The strengths of our study are the
large sample of prepubertal children, homogenous in terms of
age, and the extensive evaluation of inflammation and CV risk
markers. The study of this complex interplay of systems in
young individuals avoids the issue of secondary pathology
related to target-organ damage and comorbidities often
encountered in ageing populations. The availability of ABPM
and PWV data in all children is an additional major strength
and novelty of this study, as associations of MPO with these of
CV health indicators have rarely been assessed before and not
at all in young children. The assessment of the association of
MPO with renal function in children is another innovative facet
of our study.
Our study is limited by its cross-sectional design. Only a
prospective evaluation could provide unequivocal evidence on
cause–effect relationships and the usefulness of MPO as a
biomarker of emerging CV morbidity.
Conclusion
In this study, we demonstrate that MPO levels are associated
with nocturnal BP dipping and PWV, and that, among over-
weight/obese children, an association exists between MPO
levels and renal function. Therefore, the role of MPO as a rel-
evant pathogenic factor and as a biomarker of risk in obesity-
related CV morbidities is reinforced, by showing that young
overweight and obese children already present an inflamma-
tory and pro-oxidant milieu that may contribute to endothelial
impairment. Nevertheless, the mechanisms and the causal
associations involved continue to be poorly understood. More
studies are needed to enlighten the role of oxidative stress and
inflammation in the pathophysiology of disease, especially in
children, ideally with long-term follow-up studies.
Acknowledgements
The authors gratefully acknowledge the contribution of all
members of the research team and staff of Generation XXI.
Sources of funding
This project was supported by FEDER funds from Programa
Operacional Factores de Competitividade – COMPETE.
FCOMP-01-0124-FEDER-028751 and by national funds from the
European Journal of Clinical Investigation Vol 46 57
MYELOPEROXIDASE IN OVERWEIGHT AND OBESE CHILDREN
Portuguese Foundation for Science and Technology, Lisbon,
Portugal (PTDC/DTP-PIC/0239/2012), that granted the funds
for study design and data collection and analysis. Liane Cor-
reia-Costa was supported by Portuguese Foundation for
Science and Technology (grant SFRH/SINTD/95898/2013) and
Franz Schaefer was supported by the ERA-EDTA Research
Programme and the KfH Foundation for Preventive Medicine.
Conflict of interests
The authors have no conflict of interests to disclose.
Contributions
Liane Correia-Costa, Teresa Sousa, Alberto Caldas Afonso,
Antonio Guerra, Henrique Barros and Antonio-Albino Teixeira
and Ana Azevedo conceived and designed the present study
and were responsible for all the field work, as well as the data
analysis and interpretation. Franz Schaefer, Claudia Moura,
Claudia Mota and Jose Carlos Areias collaborated in the data
analysis and interpretation and performed literature research.
Manuela Morato, Dina Cosme and Joana Afonso carried out
experiments and were involved in data analysis and interpre-
tation. All authors were involved in writing the manuscript and
had final approval of the submitted and published versions.
Address
EPIUnit - Institute of Public Health, University of Porto, Rua
das Taipas n 135, 4050-600 Porto, Portugal (L. Correia-Costa,
D. Cosme, A. Caldas Afonso, H. Barros, A. Azevedo); Division
of Pediatric Nephrology, Integrated Pediatric Hospital, Centro
Hospitalar S~ao Jo~ao, Alameda Prof. Herna^ni Monteiro, 4200-319
Porto, Portugal (L. Correia-Costa, A. Caldas Afonso); Depart-
ment of Pharmacology and Therapeutics, Faculty of Medicine
of University of Porto, Alameda Prof. Herna^ni Monteiro, 4200-
319 Porto, Portugal (T. Sousa, M. Morato, D. Cosme,
J. Afonso, A. Albino-Teixeira); MedInUP - Center for Drug
Discovery and Innovative Medicines, University of Porto,Ala-
meda Prof. Herna^ni Monteiro, 4200-319 Porto, Portugal (T.
Sousa, M. Morato, A. Albino-Teixeira); Laboratory of Pharma-
cology, Department of Drug Sciences, Faculty of Pharmacy of
Porto, REQUIMTE, University of Porto, Rua de Jorge Viterbo
Ferreira, n 228 4050-313 Porto, Portugal (M. Morato); Division
of Pediatric Cardiology, Integrated Pediatric Hospital, Centro
Hospitalar S~ao Jo~ao, Alameda Prof. Herna^ni Monteiro, 4200-319
Porto, Portugal (C. Moura, C. Mota, J. Carlos Areias); Division
of Pediatric Nutrition, Integrated Pediatric Hospital, Centro
Hospitalar S~ao Jo~ao, Alameda Prof. Herna^ni Monteiro, 4200-319
Porto, Portugal (A. Guerra); Division of Pediatric Nephrology,
Center for Pediatrics and Adolescent Medicine, University of
Heidelberg, Im Neuenheimer Feld 672, 69120 Heidelberg,
Germany (F. Schaefer); Department of Clinical Epidemiology,
Predictive Medicine and Public Health, Faculty of Medicine of
University of Porto, Alameda Prof. Hernaˆni Monteiro, 4200-319
Porto, Portugal (H. Barros, A. Azevedo).
Correspondence to: Liane Correia-Costa, Instituto de Saude
Publica da Universidade do Porto (ISPUP), Rua das Taipas n
135, 4050-600 Porto, Portugal. Tel.: +351 222 061 820; fax:
+351 222 061 821; e-mail: liane@med.up.pt
Received 16 March 2015; accepted 1 November 2015
References
1 Montero D, Walther G, Perez-Martin A, Roche E, Vinet A.
Endothelial dysfunction, inflammation, and oxidative stress in obese
children and adolescents: markers and effect of lifestyle
intervention. Obes Rev 2012;13:441–55.
2 Mauras N, Delgiorno C, Kollman C, Bird K, Morgan M, Sweeten S
et al. Obesity without established comorbidities of the metabolic
syndrome is associated with a proinflammatory and prothrombotic
state, even before the onset of puberty in children. J Clin Endocrinol
Metab 2010;95:1060–8.
3 Codoner-Franch P, Boix-Garcia L, Simo-Jorda R, Del Castillo-
Villaescusa C, Maset-Maldonado J, Valls-Belles V et al. Is obesity
associated with oxidative stress in children? Int J Pediatr Obes
2010;5:56–63.
4 Van der Veen BS, de Winther MPJ, Heeringa P.
Myeloperoxidase: molecular mechanisms of action and their
relevance to human health and disease. Antioxid Redox Signal
2009;11:2899–937.
5 Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of
myeloperoxidase-catalyzed oxidation, is markedly elevated in low
density lipoprotein isolated from human atherosclerotic intima.
J Clin Invest 1997;99:2075–81.
6 Andrade VL, Petruceli E, Belo VA, Andrade-Fernandes CM,
Caetano Russi CV, Bosco AA et al. Evaluation of plasmatic MMP-8,
MMP-9, TIMP-1 and MPO levels in obese and lean women. Clin
Biochem 2012;45:412–5.
7 Nijhuis J, Rensen SS, Slaats Y, van Dielen FMH, Buurman WA,
Greve JWM. Neutrophil activation in morbid obesity, chronic
activation of acute inflammation. Obesity 2009;17:2014–8.
8 Van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine
RJ, Teerlink T. Hyperglycemia and oxidative stress strengthen
the association between myeloperoxidase and blood pressure.
Hypertension 2010;55:1366–72.
9 Tang WHW, Brennan M-L, Philip K, Tong W, Mann S, Van Lente F
et al. Plasma myeloperoxidase levels in patients with chronic heart
failure. Am J Cardiol 2006;98:796–9.
10 Vita JA, Brennan M-L, Gokce N, Mann SA, Goormastic M,
Shishehbor MH et al. Serum myeloperoxidase levels independently
predict endothelial dysfunction in humans. Circulation
2004;110:1134–9.
11 Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, M€unzel T
et al. Myeloperoxidase serum levels predict risk in patients with
acute coronary syndromes. Circulation 2003;108:1440–5.
12 Shao B, Pennathur S, Heinecke JW. Myeloperoxidase targets
apolipoprotein A-I, the major high density lipoprotein protein,
for site-specific oxidatzion in human atherosclerotic lesions. J Biol
Chem 2012;287:6375–86.
58 ª 2015 Stichting European Society for Clinical Investigation Journal Foundation
L. CORREIA-COSTA ET AL. www.ejci-online.com
13 Tsai M-S, Shaw H-M, Li Y-J, Lin M-T, Lee W-T, Chan K-S.
Myeloperoxidase in chronic kidney disease: role of visceral fat.
Nephrology 2014;19:136–42.
14 Kitabayashi C, Naruko T, Sugioka K, Yunoki K, Nakagawa M,
Inaba M et al. Positive association between plasma levels of
oxidized low-density lipoprotein and myeloperoxidase after
hemodialysis in patients with diabetic end-stage renal disease.
Hemodial Int 2013;17:557–67.
15 Upadhyay A, Larson MG, Guo C-Y, Vasan RS, Lipinska I, O’Donnell
CJ et al. Inflammation, kidney function and albuminuria in the
FraminghamOffspring cohort.Nephrol Dial Transplant 2011;26:920–6.
16 Olza J, Aguilera CM, Gil-Campos M, Leis R, Bueno G, Martınez-
Jimenez MD et al. Myeloperoxidase is an early biomarker of
inflammation and cardiovascular risk in prepubertal obese children.
Diabetes Care 2012;35:2373–6.
17 Montero D, Walther G, Perez-Martin A, Mercier CS, Gayrard S,
Vicente-Salar N et al. Effects of a lifestyle program on vascular
reactivity in macro- and microcirculation in severely obese
adolescents. J Clin Endocrinol Metab 2014;99:1019–26.
18 Savino A, Pelliccia P, Chiarelli F, Mohn A. Obesity-related renal
injury in childhood. Horm Res Paediatr 2010;73:303–11.
19 Larsen PS, Kamper-Jørgensen M, Adamson A, Barros H, Bonde JP,
Brescianini S et al. Pregnancy and birth cohort resources in europe: a
large opportunity for aetiological child health research. Paediatr
Perinat Epidemiol 2013;27:393–414.
20 Olza J, Aguilera CM, Gil-Campos M, Leis R, Bueno G, Valle M et al.
Waist-to-height ratio, inflammation and CVD risk in obese children.
Public Health Nutr 2014;17:2378–85.
21 Dur~ao C, Severo M, Oliveira A, Moreira P, Guerra A, Barros H et al.
Evaluating the effect of energy-dense foods consumption on
preschool children’s body mass index: a prospective analysis from 2
to 4 years of age. Eur J Nutr 2014;54:835–43.
22 De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann
J. Development of a WHO growth reference for school-aged
children and adolescents. Bull World Health Organ 2007;85:660–7.
23 Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard
definition for child overweight and obesity worldwide: international
survey. BMJ 2000;320:1240–3.
24 Urbina E, Alpert B, Flynn J, Hayman L, Harshfield GA, Jacobson M
et al. Ambulatory Blood Pressure Monitoring in Children and
Adolescents: recommendations for standard assessment a scientific
statement from the American Heart Association Atherosclerosis,
Hypertension and Obesity in Youth Committee of the of the council
on card. Hypertension 2008;52:433–51.
25 Zappitelli M, Parvex P, Joseph L, Paradis G, Grey V, Lau S et al.
Derivation and validation of cystatin C-based prediction equations
for GFR in children. Am J Kidney Dis 2006;48:221–30.
26 Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC,
Vandenbroucke JP. The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement:
guidelines for reporting observational studies. J Clin Epidemiol
2008;61:344–9.
27 Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of
reporting guidelines for health research. Eur J Clin Invest 2010;40:35–53.
28 Ruperez AI, Lopez-Guarnido O, Gil F, Olza J, Gil-Campos M, Leis R
et al. Paraoxonase 1 activities and genetic variation in childhood
obesity. Br J Nutr 2013;110:1639–47.
29 Codo~ner-Franch P, Tavarez-Alonso S, Simo-Jorda R, Laporta-Martın
P, Carratala-Calvo A, Alonso-Iglesias E. Vitamin D status is linked
to biomarkers of oxidative stress, inflammation, and endothelial
activation in obese children. J Pediatr 2012;161:848–54.
30 Stabouli S, Kotsis V, Zakopoulos N. Ambulatory blood pressure
monitoring and target organ damage in pediatrics. J Hypertens
2007;25:1979–86.
31 Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G et al.
Prognostic value of ambulatory and home blood pressures
compared with office blood pressure in the general population:
follow-up results from the Pressioni Arteriose Monitorate e Loro
Associazioni (PAMELA) study. Circulation 2005;111:1777–83.
32 Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn
M. Predictors of all-cause mortality in clinical ambulatory
monitoring: unique aspects of blood pressure during sleep.
Hypertension 2007;49:1235–41.
33 Ben-Dov IZ, Bursztyn M. Ambulatory blood pressure monitoring in
childhood and adult obesity. Curr Hypertens Rep 2009;11:133–42.
34 Merchant N, Rahman ST, Ahmad M, Parrott JM, Johnson J,
Ferdinand KC et al. Changes in biomarkers and 24 hours blood
pressure in hypertensive African Americans with the metabolic
syndrome: comparison of amlodipine/olmesartan versus
hydrochlorothiazide/losartan. J Am Soc Hypertens 2013;7:386–94.
35 Westerstahl M, Hedvall Kallerman P, Hagman E, Ek AE, R€ossner
SM, Marcus C. Nocturnal blood pressure non-dipping is prevalent
in severely obese, prepubertal and early pubertal children. Acta
Paediatr 2014;103:225–30.
36 Marcovecchio ML, Patricelli L, Zito M, Capanna R, Ciampani M,
Chiarelli F et al. Ambulatory blood pressure monitoring in obese
children: role of insulin resistance. J Hypertens 2006;24:2431–6.
37 Srinivasan SR, Bao W, Wattigney WA, Berenson GS. Adolescent
overweight is associated with adult overweight and related multiple
cardiovascular risk factors: the Bogalusa Heart Study. Metabolism
1996;45:235–40.
38 Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby
P. Macrophage myeloperoxidase regulation by granulocyte
macrophage colony-stimulating factor in human atherosclerosis and
implications in acute coronary syndromes. Am J Pathol 2001;158:879–
91.
39 Thukkani AK, McHowat J, Hsu F-F, Brennan M-L, Hazen SL, Ford
DA. Identification of alpha-chloro fatty aldehydes and unsaturated
lysophosphatidylcholine molecular species in human atherosclerotic
lesions. Circulation 2003;108:3128–33.
40 Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes
mellitus and obesity in human disease. World J Diabetes 2012;3:1–6.
41 Johnson RJ, Couser WG, Chi EY, Adler S, Klebanoff SJ. New
mechanism for glomerular injury. Myeloperoxidase-hydrogen
peroxide-halide system. J Clin Invest 1987;79:1379–87.
42 Odobasic D, Kitching AR, Semple TJ, Holdsworth SR. Endogenous
myeloperoxidase promotes neutrophil-mediated renal injury, but
attenuates T cell immunity inducing crescentic glomerulonephritis.
J Am Soc Nephrol 2007;18:760–70.
European Journal of Clinical Investigation Vol 46 59
MYELOPEROXIDASE IN OVERWEIGHT AND OBESE CHILDREN
